Comparing acalabrutinib and ibrutinib in the real world: a study of 2,509 patients with chronic lymphocytic leukemia

被引：0
|
作者：
Christofyllakis, K. [1 ]
Roeker, L. [2 ]
DerSarkissian, M. [3 ]
Ryan, K. J. [4 ]
Chen, Y. [3 ]
Wahlstrom, S. K. [5 ]
Hakre, S. [6 ]
Yu, L. [3 ]
Guo, H. [3 ]
Mato, A. R. [2 ]
机构：
[1] Saarland Univ, Med Ctr, Homburg, Germany
[2] Mem Sloan Kettering Canc Ctr, New York, NY USA
[3] Anal Grp Inc, Boston, MA USA
[4] AstraZeneca, Global Med Affairs, Gaithersburg, MD USA
[5] AstraZeneca, US Patient Safety Surveillance, Wilmington, DE USA
[6] AstraZeneca, US Med Affairs, Gaithersburg, MD USA
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V159
引用
收藏
页码：35 / 36
页数：2
相关论文
共 50 条
  • [1] Comparing Acalabrutinib and Ibrutinib in the Real World: A Study of 2,509 Patients with Chronic Lymphocytic Leukemia
    Roeker, Lindsey E.
    DerSarkissian, Maral
    Ryan, Kellie J.
    Chen, Yan
    Wahlstrom, Svea K.
    Hakre, Shweta
    Yu, Louise
    Guo, Helen
    Mato, Anthony R.
    BLOOD, 2022, 140 : 4156 - 4158
  • [2] Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia
    Roeker, Lindsey E.
    DerSarkissian, Maral
    Ryan, Kellie
    Chen, Yan
    Duh, Mei Sheng
    Wahlstrom, Svea K.
    Hakre, Shweta
    Yu, Louise
    Guo, Helen
    Mato, Anthony R.
    BLOOD ADVANCES, 2023, 7 (16) : 4291 - 4301
  • [3] Real World Treatment Patterns in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Switching from First Line Ibrutinib to Acalabrutinib
    Jacobs, Ryan
    Wang, Ruibin
    He, Jinghua
    Lu, Xiaoxiao
    Wu, Linda
    Khan, Wasiulla
    Qureshi, Zaina P.
    Levy, Moshe Yair
    BLOOD, 2022, 140 : 8017 - 8018
  • [4] Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib
    Awan, Farrukh T.
    Schuh, Anna
    Brown, Jennifer R.
    Furman, Richard R.
    Pagel, John M.
    Hillmen, Peter
    Stephens, Deborah M.
    Woyach, Jennifer
    Bibikova, Elena
    Charuworn, Prista
    Frigault, Melanie M.
    Hamdy, Ahmed
    Izumi, Raquel
    Linghu, Bolan
    Patel, Priti
    Wang, Min Hui
    Byrd, John C.
    BLOOD ADVANCES, 2019, 3 (09) : 1553 - 1562
  • [5] Acalabrutinib versus ibrutinib in relapsed chronic lymphocytic leukemia
    Stocker, Nicolas
    HEMATOLOGIE, 2021, 27 (06): : 259 - 260
  • [6] Phase 2 study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia
    Rogers, Kerry
    Thompson, Philip
    Allan, John
    Coleman, Morton
    Sharman, Jeff
    Cheson, Bruce D.
    Izumi, Raquel
    Frigault, Melanie M.
    Quah, Cheng
    Raman, Rakesh K.
    Wang, Min Hui
    Kipps, Thomas J.
    LEUKEMIA & LYMPHOMA, 2020, 61 : 4 - 5
  • [7] Phase 2 Study of Acalabrutinib in Ibrutinib-Intolerant Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
    O'Brien, Susan M.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (07) : 22 - 23
  • [8] Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia
    Rogers, Kerry A.
    Thompson, Philip A.
    Allan, John N.
    Coleman, Morton
    Sharman, Jeff P.
    Cheson, Bruce D.
    Jones, Daniel
    Izumi, Raquel
    Frigault, Melanie M.
    Quah, Cheng
    Raman, Rakesh K.
    Patel, Priti
    Wang, Min Hui
    Kipps, Thomas J.
    HAEMATOLOGICA, 2021, 106 (09) : 2364 - 2373
  • [9] Real-World Adherence to First-Line Ibrutinib and Acalabrutinib Single-Agent Among Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    Lu, Xiaoxiao
    Emond, Bruno
    Qureshi, Zaina
    He, Jinghua
    Qian, Yi
    Huang, Qing
    Lefebvre, Patrick
    Lafeuille, Marie-Helene
    Jacobs, Ryan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S280 - S281
  • [10] Mutational profile in previously treated patients with chronic lymphocytic leukemia progression on acalabrutinib or ibrutinib
    Woyach, Jennifer A.
    Jones, Daniel
    Jurczak, Wojciech
    Robak, Tadeusz
    Illes, Arpad
    Kater, Arnon P.
    Ghia, Paolo
    Byrd, John C.
    Seymour, John F.
    Long, Susan
    Mohamed, Nehad
    Benrashid, Samon
    Lai, Tzung-Huei
    De Jesus, Gary
    Lai, Richard
    de Bruin, Gerjan
    Rule, Simon
    Munugalavadla, Veerendra
    BLOOD, 2024, 144 (10) : 1061 - 1068
12345